

Press Briefing Schedule At-a-Glance

All on-site Press Briefings are located in McCormick Place, Lakeside Building E353a

Monday, May 22 Pre-Meeting Briefing	Wednesday, May 31 Pre-Meeting Briefing on LBAs	Saturday, June 3 On-Site Briefing	Sunday, June 4 On-Site Briefing
<p>Embargo lifts at 5:00 PM (ET) on May 25 Press Briefing Time: 4:00-5:30 PM (ET) <i>Virtual event conducted via live teleconference and webinar</i></p> <p>7003: Efficacy and safety results from the COMMANDS trial: A phase 3 study evaluating luspatercept vs epoetin alfa in erythropoiesis-stimulating agent (ESA)-naive transfusion-dependent (TD) patients (pts) with lower-risk myelodysplastic syndromes (LR-MDS).</p> <p>5500: KEYNOTE-826: Final overall survival results from a randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer.</p> <p>4163: Minimally invasive versus open distal pancreatectomy for resectable pancreatic cancer (DIPLOMA): An international randomised trial.</p> <p>12001: Effect of a telephone-based weight loss intervention (WLI) on weight at 12-months in women with early breast cancer: Results from the Breast Cancer Weight Loss (BWEL) trial.</p> <p>6546: Racial disparities in cancer mortality in patients with gastrointestinal malignancies following Medicaid expansion.</p> <p>1502: Childhood leukemia survival in the US-Mexico border: Building sustainable leukemia care using health systems strengthening models.</p>	<p>Press Briefing Time: 8:30-10:00 AM (CT)/9:30-11:00 AM (ET) <i>Virtual event conducted via live teleconference and webinar</i></p> <p>LBA500: Phase III NATALEE trial of ribociclib + endocrine therapy as adjuvant treatment in patients with HR+/HER-early-breast cancer Embargo lifts Friday, June 2 at 7:00 AM (CT)</p> <p>LBA5511: An international randomized phase III trial comparing radical hysterectomy and pelvic node dissection (RH) vs simple hysterectomy and pelvic node dissection (SH) in patients with low-risk early-stage cervical cancer (LRESCC). A Gynecologic Cancer Intergroup study led by the Canadian Cancer Trials Group (CTG CX.5-SHAPE). Embargo lifts Friday, June 2 at 7:00 AM (CT)</p> <p>LBA5506: Durvalumab with paclitaxel/carboplatin (PC) and bevacizumab (bev), followed by maintenance durvalumab, bev, and olaparib in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumor BRCA1/2 mutation (non-tBRCAm): Results from the randomized, placebo (pbo)-controlled phase III DUO-O trial. Embargo lifts Saturday, June 3 at 7:00 AM (CT)</p>	<p>Press Briefing Time: 1:00-2:00 PM (CT) <i>In-person and livestreamed</i></p> <p>LBA2: PROSPECT: A randomized phase III trial of neoadjuvant chemoradiation versus neoadjuvant FOLFOX chemotherapy with selective use of chemoradiation, followed by total mesorectal excision (TME) for treatment of locally advanced rectal cancer (LARC) (Alliance N1048). Embargo lifts Sunday, June 4 at 7:00 AM (CT)</p> <p>LBA3: Overall survival analysis from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR-mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC). Embargo lifts Sunday, June 4 at 7:00 AM (CT)</p> <p>LBA1: INDIGO: A global, randomized, double-blinded, phase 3 study of vorasidenib versus placebo in patients with residual or recurrent grade 2 glioma with an IDH1/2 mutation. Embargo lifts Sunday, June 4 at 7:00 AM (CT)</p> <p>LBA4: SWOG S1826, a Randomized Study of Nivolumab(N)-AVD Versus Brentuximab Vedotin(BV)-AVD in Advanced Stage (AS) Classic Hodgkin Lymphoma (HL). Embargo lifts Sunday, June 4 at 7:00 AM (CT)</p> <p>LBA5507: Phase III MIRASOL (GOG 3045/ENGOT-ov55) study: Initial report of mirvetuximab soravtansine vs. investigator's choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression Embargo lifts Sunday, June 4 at 7:00 AM (CT)</p>	<p>Press Briefing Time: 8:00-9:00 AM (CT) <i>In-person and livestreamed</i></p> <p>LBA3000: Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results. Embargo lifts Monday, June 5 at 7:00 AM (CT)</p> <p>LBA7505: Observation vs. radiotherapy in primary mediastinal B-cell lymphoma patients with complete response to standard immunochemotherapy: The IELSG37 randomized trial. Embargo lifts Tuesday, June 6 at 7:00 AM (CT)</p>